Nano‑X Imaging Ltd. (NASDAQ: NNOX) secured U.S. Food and Drug Administration clearance for its TAP2D cloud‑enabled image‑enhancement capability on its ARC and ARC X digital tomosynthesis systems. The 510(k) approval allows the devices to generate a 2‑D image directly from a tomosynthesis scan, giving clinicians both 3‑D and 2‑D views from a single acquisition without additional radiation exposure.
TAP2D leverages the company’s proprietary digital X‑ray source and AI algorithms to reconstruct a high‑resolution 2‑D projection from the volumetric data set. The feature is delivered as a remote software update, meaning existing customers can upgrade their systems without new hardware, and it preserves the low‑dose advantage that has been a hallmark of Nano‑X’s technology.
The clearance moves Nano‑X closer to positioning the ARC as a primary diagnostic modality in the United States, a status it already holds in Europe under its CE Mark. By eliminating the adjunctive‑use limitation, the company can expand its addressable market, accelerate commercial deployment, and strengthen its competitive position against established X‑ray tube manufacturers.
Nano‑X reiterated its 2026 revenue guidance of more than $35 million, a target that builds on Q3 2025 revenue of $3.4 million versus $3.0 million in Q3 2024. The company’s management highlighted that the TAP2D approval is a key driver of the guidance, as the feature is expected to increase adoption and enable new revenue streams from cloud‑based services.
CEO Erez Meltzer said the clearance “provides important regulatory insights as we work toward our goal of removing the adjunctive use in the United States.” He added that the remote update model underscores Nano‑X’s strategy of integrating hardware, AI, and cloud software to deliver end‑to‑end solutions.
Market participants reacted positively to the clearance, citing its potential to broaden the company’s U.S. footprint. Analysts noted that while the approval is a significant milestone, Nano‑X still faces financial headwinds, including ongoing losses and a low Altman Z‑Score, and must ultimately achieve primary‑use status to fully realize the commercial upside.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.